Physician profile
Rodney Jamil
NPI 1063694552
$5,651.30
in general payments reported to CMS, 2019-2025
43 companies · $2,593 in 2025
The $2,593 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $224 · 2021: $70.81 · 2022: $20.09 · 2023: $550 · 2024: $1,525 · 2025: $2,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,719 · Education: $950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.96 |
| Education | $949.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $738.95 | 2019-2025 | Imfinzi, Calquence |
| Astellas Pharma US INC | $669.50 | 2023-2025 | Padcev, Xtandi, Vyloy |
| Novartis Pharmaceuticals Corporation | $421.97 | 2023-2025 | |
| Janssen Biotech, INC. | $378.92 | 2023-2025 | Rybrevant, Carvykti, Erleada |
| Daiichi Sankyo INC. | $342.04 | 2024-2025 | Enhertu, Datroway |
| Glaxosmithkline, LLC. | $291.96 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Seagen INC. | $230.71 | 2023-2025 | Tukysa, Adcetris |
| Pfizer INC. | $229.16 | 2023-2025 | |
| Abbvie INC. | $201.88 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $194.21 | 2021-2025 | Opdivo, Eliquis |
| Merck Sharp & Dohme LLC | $188.94 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Incyte Corporation | $185.54 | 2023-2025 | Jakafi, Jakafi, Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $166.23 | 2023-2025 | |
| Novocure INC. | $143.51 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Lilly USA, LLC | $134.89 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $126.57 | 2024-2025 | Opdivo |
| Stemline Therapeutics INC. | $125.38 | 2023-2025 | Orserdu |
| Eisai INC. | $108.00 | 2023-2025 | |
| Abbott Laboratories | $87.19 | 2024 | Proclaim |
| Myriad Genetic Laboratories, INC. | $74.04 | 2023-2025 | Myrisk |
| Takeda Pharmaceuticals U.S.A., INC. | $70.35 | 2025 | Alunbrig, Iclusig |
| Emd Serono, INC. | $57.07 | 2023-2024 | |
| Genzyme Corporation | $51.18 | 2025 | |
| Fresenius Kabi USA, LLC | $40.35 | 2023-2024 | Stimufend |
| Array Biopharma INC | $39.84 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Exelixis INC. | $33.65 | 2025 | Cabometyx |
| Genentech USA, INC. | $27.00 | 2025 | Venclexta |
| Beone Medicines USA, INC. | $24.55 | 2025 | Tevimbra |
| Blueprint Medicines Corporation | $23.70 | 2025 | Ayvakit |
| Syndax Pharmaceuticals, INC. | $20.78 | 2025 | Revuforj |
| Caris Mpi, INC. | $20.39 | 2025 | Mi Cancer Seek |
| Sirtex Medical INC | $20.07 | 2023 | Sir-Spheres Microspheres |
| Kite Pharma, INC. | $19.55 | 2023 | Yescarta |
| Adc Therapeutics America, INC. | $19.20 | 2025 | |
| Taiho Oncology, INC. | $18.58 | 2025 | |
| Geron Corporation | $18.51 | 2025 | Rytelo |
| Gilead Sciences, INC. | $17.52 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $17.28 | 2023 | Libtayo |
| Genmab U.S., INC. | $16.25 | 2023 | Tivdak |
| Tersera Therapeutics LLC | $14.37 | 2023 | Zoladex |
| Aveo Pharmaceuticals, INC. | $14.28 | 2025 | |
| Puma Biotechnology, INC. | $13.70 | 2023 | |
| Amgen INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.